Ind-Swift Laboratories
Ind-Swift Laboratories Share Price Chart
Ind-Swift Laboratories last traded at ₹361.30 (2026-10-13). Over the past month the stock moved -4.2%, three months the stock moved +165.7%, year the stock moved +244.4%. Its closing range over 52 weeks is ₹90.70 – ₹414.40, with the latest close 12.8% below the high.
Closing prices up to 2026-10-13.
About Ind-Swift Laboratories
Incorporated in 1995, Ind-Swift Laboratories Ltd is in the business of Bulk Drugs & Pharmaceuticals[1]
Business Overview:[1] ISLL is a global manufacture of APIs, Intermediates and formulation (through group collaboration). It caters to the API needs of regulated markets including USFDA, EDQM, PMDA, ANVISA, EU-GMP, KFDA, NMO, ANSM, Cofepris, TGA, WHO, ROW. ISLL is present in all stages of drug substance/product including new chemical/molecular research to formulation development. Company manufactures APIs towards Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. It also holds global leadership positions in the Macrolide Antibiotic segment.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Ind-Swift Laboratories reported sales of ₹191.00 crore (+24.8%) and net profit of ₹25.00 crore (+177.8%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 191.00 | 33.00 | 17.00 | 25.00 | 2.84 |
| Mar 2026 | 170.00 | 21.00 | 12.00 | 15.00 | 1.74 |
| Dec 2025 | 151.00 | 4.00 | 2.80 | 10.00 | 1.17 |
| Sep 2025 | 153.00 | 1.00 | 1.00 | 8.00 | 0.98 |
| Jun 2025 | 153.00 | 4.00 | 2.40 | 9.00 | 1.45 |
| Mar 2025 | 138.00 | -9.00 | -7.00 | 222.00 | 36.67 |
| Dec 2024 | 129.00 | -7.00 | -5.00 | -5.00 | -0.93 |
| Sep 2024 | 12.00 | -12.00 | -99.00 | 0.00 | 0.07 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -95.9% | -55.2% | -73.9% | +363.6% | +1175.0% | +17.1% | +23.2% | +24.8% |
| Operating profit growth | -118.2% | -113.5% | -109.9% | – | – | – | – | +725.0% |
| Net profit growth | -100.0% | -126.3% | -55.1% | +800.0% | – | – | -93.2% | +177.8% |
| EPS growth | -98.7% | -128.3% | -56.1% | +806.3% | +1300.0% | – | -95.3% | +95.9% |
| OPM % | -99.0% | -5.0% | -7.0% | 2.4% | 1.0% | 2.8% | 12.0% | 17.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Ind-Swift Laboratories reported sales of ₹641.00 crore (+14.1%) and net profit of ₹41.00 crore (-83.6%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 641.00 | 45.00 | 7.00 | 41.00 | 4.77 |
| Mar 2025 | 562.00 | -19.00 | -3.00 | 250.00 | 41.32 |
| Mar 2024 | 1,281 | 252.00 | 20.00 | 421.00 | 71.24 |
| Mar 2023 | 1,207 | 229.00 | 19.00 | 48.00 | 8.06 |
| Mar 2022 | 1,039 | 202.00 | 19.00 | -2.00 | -0.36 |
| Mar 2021 | 891.00 | 183.00 | 21.00 | -3.00 | -0.53 |
| Mar 2020 | 780.00 | 144.00 | 19.00 | -21.00 | -3.59 |
| Mar 2019 | 757.00 | 126.00 | 17.00 | 29.00 | 6.09 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -1.0% | +3.0% | +14.2% | +16.6% | +16.2% | +6.1% | -56.1% | +14.1% |
| Operating profit growth | -6.0% | +14.3% | +27.1% | +10.4% | +13.4% | +10.0% | -107.5% | – |
| Net profit growth | +31.8% | -172.4% | – | – | – | +777.1% | -40.6% | -83.6% |
| EPS growth | +25.6% | -158.9% | – | – | – | +783.9% | -42.0% | -88.5% |
| OPM % | 17.0% | 19.0% | 21.0% | 19.0% | 19.0% | 20.0% | -3.0% | 7.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Ind-Swift Laboratories.
Get Free AI Stock Analysis FREE →Latest News
-
Ind-Swift Laboratories Ltd leads gainers in 'B' group - business-standard.com
-
Ind-Swift Laboratories Ltd leads gainers in 'B' group - business-standard.com
-
Ind-Swift Laboratories Ltd leads gainers in 'B' group - business-standard.com
-
Ind-Swift Laboratories Passes Four Special Resolutions via Postal Ballot, Approves Leadership Changes - scanx.trade
Frequently Asked Questions
What is Ind-Swift Laboratories's current stock price?
Ind-Swift Laboratories shares were last quoted at ₹361.30 (+0.1% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Ind-Swift Laboratories?
Ind-Swift Laboratories has a price-to-earnings (P/E) ratio of 61.39 and a price-to-book (P/B) ratio of 2.50. The industry P/E is 53.33.
What is the 52-week high and low of Ind-Swift Laboratories?
The 52-week high of Ind-Swift Laboratories is ₹419.05 and the 52-week low is ₹87.00.
What is the market cap of Ind-Swift Laboratories?
The market capitalisation of Ind-Swift Laboratories is about ₹3,518.03 crore.
How did Ind-Swift Laboratories perform in its latest quarterly results?
In the latest quarter (Jun 2026), Ind-Swift Laboratories reported sales of ₹191.00 crore (+24.8%) and net profit of ₹25.00 crore (+177.8%), compared with the same quarter last year.
Is Ind-Swift Laboratories a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Ind-Swift Laboratories has a 3-year ROE of 6.00%, 3-year profit growth of -7.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Ind-Swift Laboratories?
Promoters hold about 42.93% of Ind-Swift Laboratories.
Which sector does Ind-Swift Laboratories belong to?
Ind-Swift Laboratories belongs to the Pharmaceuticals & Drugs sector.